Company Overview of Catalyst Biosciences, Inc.
Catalyst Biosciences, Inc., a clinical-stage company, focuses on the development of catalytic biopharmaceutical products based on engineered human proteases. It focuses on drug discovery for hemostasis, hemophilia, non-hemophilic bleeding, and complement-driven diseases, including the prevention of delayed graft function and inflammation. The company develops FVIIa, an enzyme that initiates blood clotting; FIX, a recombinant human factor IX for treating acute bleeding episodes in hemophilia B patients; and FXa, a pro-coagulant and bypass agent to control bleeding during surgery and trauma for hemophilia inhibitor patients and general population. It develops drugs for ischemia reperfusion inj...
260 Littlefield Avenue
South San Francisco, CA 94080-7019
Founded in 2002
Key Executives for Catalyst Biosciences, Inc.
Chief Executive Officer, President and Director
Co-Founder and Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2015.
Catalyst Biosciences, Inc. Key Developments
Catalyst Biosciences, Inc. Announces Positive Results from A Phase 1 Clinical Trial of CB 813d/PF-05280602
Jun 24 15
Catalyst Biosciences, Inc. announced positive results from a Phase 1 clinical trial of CB 813d/PF-05280602, its next-generation and long-acting coagulation Factor VIIa. Results showed that single doses of CB 813d were well tolerated when administered to hemophilia A and B patients, and there were no instances of antibody response or thrombosis. CB 813d demonstrated pharmacological efficacy as measured by significant shortening of aPTT (activated partial thromboplastin time) and PT (prothrombin time) for up to 48 hours post dosing. The results were presented in a poster session at the International Society on Thrombosis and Haemostasis (ISTH) Meeting being held in Toronto, Canada from June 20 to 25, 2015. CB 813d is an improved next-generation and long-acting coagulation Factor VIIa variant and the company's most advanced clinical development program. The open label, multicenter Phase 1 trial evaluated the safety and tolerability of CB 813d as well as pharmacokinetics, pharmacodynamics and coagulation (i.e., clot forming) activity of CB 813d when given intravenously to 25 non-bleeding hemophilia patients in single ascending dose cohorts who were then observed for up to 60 days post treatment. Evidence of pharmacological activity was observed with dose-dependent changes in aPTT, PT, PF1+2 (prothrombin fragments 1 + 2), and TGA (thrombin generation activity). CB 813d was well tolerated across all dose groups. No treatment emergent serious adverse events were observed. There was no evidence of antibody immune or "inhibitor" response to treatment with CB 813d at days 15, 30 or 60 of the study. The company plans to initiate a clinical efficacy trial in hemophilia A and B "inhibitor" patients in 2016. In addition to the FVIIa clinical results, the company and its collaborators, also presented preclinical data at the meeting related to the company's proprietary coagulation compounds, next generation variants of Factor VIIa, Factor IX, and Factor Xa. Factor IX: CB 2679d/ISU 304 is a next-generation coagulation Factor IX variant that is in advanced preclinical development. In an oral presentation entitled CB-FIX: an improved second generation FIX drug candidate, Madison et al. evaluated the procoagulant activity of the company's Factor IX compared with existing coagulation factors such as BeneFIXÂ® (coagulation factor IX (recombinant)) and other advanced second generation FIX variants. CB-FIX exhibited enhanced procoagulant activity, improved efficacy in inhibiting blood loss, and prolonged duration of action in bleeding and non-bleeding preclinical models. Based on these findings, CB-FIX may represent a novel second-generation FIX variant. Factor Xa: CB-FXa is an advanced lead molecule that is in preclinical research. In an oral presentation entitled CB-FXa: an improved second generation FXa variant, Madison et al. evaluated the procoagulant activity of the company's FXa variant. CB-FXa exhibited enhanced potency, greater co-factor dependence, and improved safety (in murine models) compared with various FXa proteins, including an existing clinical candidate. Based on improved in vitro and in vivo properties, CB-FXa may represent a novel second-generation FXa variant.
Catalyst Biosciences, Inc. Announces Multiple Data Presentations at the 2015 International Society on Thrombosis and Haemostatsis Meeting in Toronto, Canada
Jun 16 15
Catalyst Biosciences, Inc. announced that data from three of its product candidates will be presented at the International Society on Thrombosis and Haemostatsis (ISTH) Meeting being held in Toronto, Canada from June 20 to 25, 2015. The presentations, being made by Catalyst and its collaborators, are as follows: Factor VIIa: CB 813d/PF-05280602 is an improved next-generation and long-acting coagulation Factor VIIa variant and Catalyst's most advanced clinical development program. Factor IX: CB 2679d/ISU 304 is a next-generation coagulation Factor IX variant that is in advanced preclinical development. Factor Xa: a Factor Xa variant that is in preclinical research.
Catalyst Biosciences, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 03:00 PM
May 28 15
Catalyst Biosciences, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 03:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Nassim Usman, Chief Executive Officer and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 29, 2015
March 5, 2015
January 22, 2015